scholarly journals Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone

2021 ◽  
Vol 14 (2) ◽  
pp. 100993
Author(s):  
Shuzhong Liu ◽  
An Song ◽  
Yunxiao Wu ◽  
Siyuan Yao ◽  
Muchuan Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Epithelial Mesenchymal Transition ◽  
Metastatic Breast ◽  
Mesenchymal Transition ◽  
Immune Infiltration

scholarly journals Epithelial Mesenchymal Transition (EMT) in Metastatic Breast Cancer in Omani Women

2017 ◽  
Vol 10 (1-3) ◽  
pp. 25-37 ◽  
Author(s):  
Ritu Lakhtakia ◽  
Adil Aljarrah ◽  
Muhammad Furrukh ◽  
Shyam S. Ganguly
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Epithelial Mesenchymal Transition ◽  
Metastatic Breast ◽  
Mesenchymal Transition

Epithelial-mesenchymal transition in patients with HER2+ metastatic breast cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 623-623 ◽  
Author(s):  
A. Giordano ◽  
M. Mego ◽  
B. Lee ◽  
S. Anfossi ◽  
C. A. Parker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Epithelial Mesenchymal Transition ◽  
Metastatic Breast ◽  
Mesenchymal Transition

scholarly journals Maintenance of epithelial traits and resistance to mesenchymal reprogramming promote proliferation in metastatic breast cancer

2020 ◽  
Author(s):  
Laura Eichelberger ◽  
Massimo Saini ◽  
Helena Domínguez Moreno ◽  
Corinna Klein ◽  
Johanna M. Bartsch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Epithelial Mesenchymal Transition ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Mesenchymal Transition ◽  
Cancer Subtypes ◽  
Stage Iv Breast Cancer

AbstractDespite important advances in the treatment of breast cancer, the 5-year survival rate for patients with distant metastasis remains less than 30%. Metastasis is a complex, multi-step process beginning with local invasion and ending with the outgrowth of systemically disseminated cells into actively proliferating metastases that ultimately cause the destruction of vital organs. It is this last step that limits patient survival and, at the same time, remains the least understood mechanistically. Here, we focus on understanding determinants of metastatic outgrowth using metastatic effusion biopsies from stage IV breast cancer patients. By modelling metastatic outgrowth through xenograft transplantation, we show that tumour initiation potential of patient-derived metastatic breast cancer cells across breast cancer subtypes is strongly linked to high levels of EPCAM expression. Breast cancer cells with high EPCAM levels are highly plastic and, upon induction of epithelial-mesenchymal transition (EMT), readily adopt mesenchymal traits while maintaining epithelial identity. In contrast, low EPCAM levels are caused by the irreversible reprogramming to a mesenchymal state with concomitant suppression of metastatic outgrowth. The ability of breast cancer cells to retain epithelial traits is tied to a global epigenetic program that limits the actions of EMT-transcription factor ZEB1, a suppressor of epithelial genes. Our results provide direct evidence that maintenance of epithelial identity is required for metastatic outgrowth while concomitant expression of mesenchymal markers enables plasticity. In contrast, loss of epithelial traits is characteristic of an irreversible mesenchymal reprogramming associated to a deficiency for metastatic outgrowth. Collectively, our data provide a framework for the intricate intercalation of mesenchymal and epithelial traits in metastatic growth.

scholarly journals Metastasis: A Bane of Breast Cancer Therapy

2020 ◽  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Progression ◽  
Cancer Metastasis ◽  
Epithelial Mesenchymal Transition ◽  
Tumour Size ◽  
Metastatic Breast ◽  
Metastatic Potential ◽  
Breast Cancer Metastasis ◽  
Mesenchymal Transition

The underlying mechanisms of metastasis in patients with breast cancer is still poorly understood. Approximately 6% of patients with breast cancer present with metastasis at the time of diagnosis. Metastatic breast cancer is difficult to treat and patients with breast cancer with distant metastasis have a significantly lower 5-year survival rate compared to patients with localised breast cancer (27% and 99%, respectively). During breast cancer progression, tumour cells first metastasise to nearby draining lymph nodes and then to distant organs, primarily bone, lungs, liver, and brain. In this brief review, the authors discuss breast cancer metastasis, the role of epithelial–mesenchymal transition and the contributions of the immune system to the metastatic process. The authors also briefly discuss whether there is any relationship between tumour size and metastatic potential, and recent advances in treatment for metastatic breast cancer. The studies highlighted suggest that immunotherapy may play a more significant role in future patient care for metastatic breast cancer.

Sign in / Sign up

Export Citation Format

Share Document